PharmX Technologies Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Tom Culver

Algemeen directeur

AU$219.3k

Totale compensatie

Percentage CEO-salaris	87.3%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tom Culver's beloning veranderd ten opzichte van PharmX Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$219k	AU$191k	AU$95k

Compensatie versus markt: De totale vergoeding ($USD 142.10K ) Tom } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 297.90K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Tom te vergelijken met de prestaties van het bedrijf.

CEO

Tom Culver

less than a year

Tenure

AU$219,292

Compensatie

Mr. Tom Culver serves as Head of Wealth & Crypto Services at Douugh Limited since January 2021. Mr. Culver is Goodments Founder & CEO. Mr. Culver is Chief Executive Officer of PharmX Technologies Limited f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Tom Culver	Chief Executive Officer	less than a year	AU$219.29k	geen gegevens
Zoe Hillier	Chief Financial Officer	3.3yrs	AU$276.23k	0.10% A$ 43.1k
James Nevile	Chief Operating Officer	3.3yrs	AU$310.49k	0% A$ 0
Sally McDow	Company Secretary	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van PHX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jayne Shaw	Independent Non-Executive Director	4.1yrs	AU$97.68k	0.46% A$ 191.9k
Andrew Jonathan Newbery	Non-Executive Director	4.8yrs	AU$185.37k	0.29% A$ 118.2k
Philip England	Non-Executive Chairman	5yrs	AU$324.28k	4.51% A$ 1.9m
Alexander Mellis	Non-Executive Independent Director	less than a year	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van PHX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

PharmX Technologies Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

PharmX Technologies Limited Announces Change of Company Secretary

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

PharmX Technologies Limited Announces Change of Company Secretary

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Less than half of directors are independent

Less than half of directors are independent

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

New major risk - Market cap size

Less than half of directors are independent

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

No independent directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

No independent directors

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

Now 20% undervalued

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

No independent directors

Corum Group Limited Launches Pharmxchange Platform

No independent directors

No independent directors

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

No independent directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

No independent directors

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur